Germany · Delayed Price · Currency is EUR Gerresheimer AG Earnings Call Transcripts
Fiscal Year 2025
-
Restated and audited 2025 financials reflect extensive compliance work, with revenue at EUR 2.3 billion and flat organic growth. Margin improvement and cash generation are key 2026 priorities, supported by the GTO transformation and planned Centor sale and refinancing.
-
Q3 and nine-month results were below expectations, with organic revenue and EBITDA declines driven by weak cosmetics and oral liquids markets. Guidance was revised downward, a transformation program was launched, and liquidity remains strong with no covenant breaches.
-
Q3 and the first nine months of 2025 were below expectations, with organic revenue and EBITDA both declining year-over-year. Guidance was revised downward, with a projected organic revenue decline of -4% to -2% and an adjusted EBITDA margin of 18.5%-19%.
-
Net debt to EBITDA and free cash flow trends were discussed, with expectations for stabilization. Operational focus includes drug delivery systems, plastics, and primary packaging glass, alongside ongoing partnerships and governance initiatives.
-
Q2 2025 saw strong reported growth from the Bormioli Pharma acquisition, but organic growth was modest due to ongoing weakness in cosmetics and oral liquids. Guidance for 2025 was lowered, with a focus on margin, cash flow, and deleveraging, while high-value solutions and biologics remain key growth drivers.
-
2025 guidance was revised down due to weak H1 demand in cosmetics and oral liquids, despite Bormioli Pharma's positive impact. Organic revenue growth is now expected at 1%-2% with a 20% adjusted EBITDA margin, and a stronger H2 is anticipated, led by GLP-1 and new launches.
-
Q1 2025 saw double-digit reported revenue and EBITDA growth driven by the Bormioli Pharma acquisition, though organic results declined due to phasing in syringes and soft cosmetics demand. Guidance for 2025 is reaffirmed, with strong order intake and high-value solutions supporting a return to organic growth from Q2 onward.
Fiscal Year 2024
-
Q4 2024 delivered a return to growth, with strong performance in biologics and the completion of the Bormioli Pharma acquisition. 2025 guidance anticipates 3%-5% organic revenue growth, margin expansion, and continued focus on integration and innovation.
-
Q3 2024 saw modest growth, with Plastics & Devices outperforming and PPG lagging due to destocking and flooding at the Morganton plant. Guidance for 2024 and 2025 was revised downward, but long-term growth in high-value products and biologics remains strong.
-
Q2 2024 saw resilient results with strong Plastics & Devices growth offsetting vial destocking, stable margins, and confirmed guidance for 2024. The Bormioli Pharma acquisition will enhance high-value solutions, and H2 is expected to show stronger growth as destocking fades.